---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-26-000036"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:17:06.216696+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xencor reports final Phase 1 data for XmAb942; predicts superior TL1A inhibition vs first-gen antibodies

## Summary
- XmAb942 achieved 74.1-day half-life; supports single SC dose every 12 weeks during maintenance.
- Modeling predicts >99% TL1A inhibition in 86% of patients during induction vs 31-40% for first-gen.
- No serious TEAEs; ADA incidence 57% across doses but 0% neutralizing at high-dose tested in Phase 2b.
- Global Phase 2b XENITH-UC enrollment on track; primary endpoint results expected H2 2027.
- First-in-human study for XmAb412 (TL1A x IL23p19) on track to start in Q3 2026.

## SEC filing metadata
- accession: 0001326732-26-000036
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673226000036/0001326732-26-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673226000036/xncr-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-26-000036
- JSON: https://secwatch.observer/filing/0001326732-26-000036.json
- Plain text: https://secwatch.observer/filing/0001326732-26-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.